Castle Biosciences receives payer coverage decisions covering 120 million lives

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx assays. These networks together provide access to more than 120 million covered lives.

Read More →